Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.46 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27641245 | 0.86 | CYP1A2 (0.55) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL3969032 | 0.83 | CYP1A2 (0.60) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL526457 | 0.81 | CYP1A2 (0.58) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL4848307 | 0.81 | CYP1A2 (0.58) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL28589683 | 0.81 | CYP1A2 (0.58) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL6768193 | 0.81 | ELANE (0.43) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL13777688 | 0.80 | KDM4E (0.62) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL3926944 | 0.79 | ELANE (0.42) | CYP1A2BACE1KDM4EALDH1A1HPGD | |
| SCHEMBL7967311 | 0.79 | CYP1A2 (0.55) | CYP1A2BACE1PDE10AKDM4EALDH1A1 | |
| SCHEMBL21848526 | 0.79 | PDE10A (0.57) | CYP1A2BACE1PDE10AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-7138401-B2 | 2-aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| US-6117884-A | 4-substituted quinoline derivatives having fungicidal activity | DAEUBLE JOHN (US) | 2000-09-12 | — | — | US | disclosed |
| EP-0925282-A1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES HAVING FUNGICIDAL ACTIVITY | DOWELANCO (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998005645-A9 | 4-SUBSTITUTED QUINOLINE DERIVATIVES HAVING FUNGICIDAL ACTIVITY | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998005645-A1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES HAVING FUNGICIDAL ACTIVITY | DOW AGROSCIENCES LLC (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | HSP90AB2P, HSP90AB1, HSP90AA1 | CYP1A2 1520/4885BACE1 4740/4885PDE10A 3524/4885 |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | HSP90AB2P, HSP90AB1, HSP90AA1 | CYP1A2 1520/4885BACE1 4740/4885PDE10A 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.